Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1998-9-9
|
pubmed:abstractText |
We previously reported that the chronic inhibition of nitric oxide (NO) synthesis increases cardiac tissue angiotensin-converting enzyme expression and causes cardiac fibrosis in rats. However, the mechanisms are not known. Transforming growth factor-beta (TGF-beta) is a key molecule that is responsible for tissue fibrosis. The present study investigated the role of TGF-beta in the pathogenesis of cardiac fibrosis. The development of cardiac fibrosis by oral administration of the NO synthesis inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) to normal rats was preceded by increases in mRNA levels of cardiac TGF-beta1 and extracellular matrix (ECM) proteins. TGF-beta immunoreactivity was increased in the areas of fibrosis. Treatment with a specific angiotensin II type 1 receptor antagonist, but not with hydralazine, completely prevented the L-NAME-induced increases in the gene expression of TGF-beta1 and ECM proteins and also prevented cardiac fibrosis. Intraperitoneal injection of neutralizing antibody against TGF-beta did not affect the L-NAME-induced increase in TGF-beta1 mRNA levels but prevented an increase in the mRNA levels of ECM protein. These results suggest that the early induction of TGF-beta1 via the angiotensin II type 1 receptor plays a major role in the development of cardiac fibrosis in this model.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/NG-Nitroarginine Methyl Ester,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Angiotensin,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0194-911X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
273-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9719054-Administration, Oral,
pubmed-meshheading:9719054-Animals,
pubmed-meshheading:9719054-Blood Pressure,
pubmed-meshheading:9719054-Body Weight,
pubmed-meshheading:9719054-Endomyocardial Fibrosis,
pubmed-meshheading:9719054-Enzyme Inhibitors,
pubmed-meshheading:9719054-Heart Rate,
pubmed-meshheading:9719054-Male,
pubmed-meshheading:9719054-NG-Nitroarginine Methyl Ester,
pubmed-meshheading:9719054-Nitric Oxide,
pubmed-meshheading:9719054-Rats,
pubmed-meshheading:9719054-Rats, Inbred WKY,
pubmed-meshheading:9719054-Receptor, Angiotensin, Type 1,
pubmed-meshheading:9719054-Receptor, Angiotensin, Type 2,
pubmed-meshheading:9719054-Receptors, Angiotensin,
pubmed-meshheading:9719054-Signal Transduction,
pubmed-meshheading:9719054-Transforming Growth Factor beta
|
pubmed:year |
1998
|
pubmed:articleTitle |
Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats.
|
pubmed:affiliation |
Research Institute of Angiocardiology and the Second Department of Internal Medicine, Kyushu University Faculty of Medicine, Fukuoka, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|